Eye­ing the 'trans­latome,' Pfiz­er ties an­oth­er knot with biotech part­ner for pre­clin­i­cal, next-gen tar­get­ed ther­a­pies

Af­ter close­ly fol­low­ing eF­FEC­TOR Ther­a­peu­tics’ work on next-gen tar­get­ed can­cer ther­a­pies in the past two years, chip­ping in its own ven­ture dol­lars and ink­ing an I/O com­bo col­lab­o­ra­tion with its PD-L1, Pfiz­er is bet­ting on a sec­ond drug can­di­date from the biotech part­ner.

The pre­clin­i­cal deal starts rel­a­tive­ly small — $15 mil­lion up­front — but Pfiz­er has com­mit­ted to $492 mil­lion in R&D fund­ing and mile­stones, as well as roy­al­ties and an op­tion to co-pro­mote in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER